UroGen reports FY2025 net loss $153.5M; ZUSDURI launch net sales $15.8M; refinances debt at 8.25%

UroGen Pharma Ltd.

FY2025 revenue $109.8M (+21% YoY); JELMYTO net sales $94M (underlying demand +7%).
ZUSDURI net sales $15.8M in initial launch; 838 activated sites, 102 unique prescribers as of Dec 31, 2025.
Permanent J Code (J9282) effective Jan 1, 2026; launch acceleration expected.
Refinanced existing term loan: $200M funded at 8.25% fixed, new $50M tranche available until June 2027.
2026 guidance: JELMYTO net sales $97-101M; total operating expenses $240-250M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.